| CAS NO: | 57381-26-7 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 2g | 电议 |
| 5g | 电议 |
| 10g | 电议 |
| Molecular Weight (MW) | 256.09 |
|---|---|
| Formula | C9H7Cl2N5 |
| CAS No. | 57381-26-7 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 2 mg/mL (7.8 mM) |
| Water:<1 mg/mL | |
| Ethanol: <1 mg/mL | |
| Other info | Chemical Name: 6-(2,5-dichlorophenyl)-1,3,5-triazine-2,4-diamine SMILES Code: NC1=NC(N)=NC(C2=CC(Cl)=CC=C2Cl)=N1 |
| Synonyms | MN1695; MN 1695; Gaslon; MN-1695; Irsogladine maleate; |
| In Vitro | In vitro activity: Irsogladine up-regulates GJIC between PC cells via regulation of the PKA pathway. It also suggests a useful adjuvant of Irsogladine to pancreatic cancer therapy. Irsogladine produces the increase of intracellular cAMP content via non-selective inhibition of PDE isozymes, which may be a key mechanism involved in its gastroprotective actions |
|---|---|
| In Vivo | Irsogladine treatment (300 and 500 mg/kg/day) resulted in a dose-dependent reduction of angiogenesis in wild-type mice by 21 and 45.3% (P < 0.02, P < 0.001), in tPA-deficient mice by 42.6 and 46% (P < 0.001, P < 0.001), and in uPA-deficient mice by 27.2 and 46% (P < 0.05, p < 0.001), respectively. Irsogladine inhibits bFGF-induced angiogenesis in wild-type, tPA-knockout, and uPA-knockout mice. |
| Animal model | Mice |
| Formulation & Dosage | 300 and 500 mg/kg |
| References | J Surg Res. 1998 Jul 1;77(2):126-31; Pancreas. 2002 Nov;25(4):373-7; Life Sci. 2004 Aug 27;75(15):1833-42. |
m.cnreagent.com